文献速递乳腺乳腺X线

影像生物标志物在更致命乳腺癌亚型中应用不足但对预后高度预测

Imaging biomarkers are underutilised but highly predictive prognostic factors for the more fatal breast cancer subtypes.
PubMed 文献 · Eur J Radiol · 2023-07-31

该研究纳入2008-2019年在本院诊断且影像与分子生物标志物数据完整的2236例乳腺癌病例,分析影像生物标志物与常规分子标志物单独及联合预测长期结局的价值。结果显示影像生物标志物对长期结局有强预测作用,而分子标志物在间叶起源乳腺癌和导管腺癌中误导性提示预后良好;整合影像生物标志物可提高诊断报告的预后准确性。

要点

  • 影像生物标志物对乳腺癌长期结局有强预测作用,在间叶起源乳腺癌和导管腺癌中可靠提示高死亡风险。
  • 分子生物标志物仅在单灶腺泡腺癌中预测结局,在多灶病例中因瘤灶间异质性而可靠性较低。
  • 间叶起源乳腺癌和导管腺癌占2236例的21%,却占乳腺癌死亡的45%。

核心结论

  • 将影像生物标志物整合入乳腺癌诊断工作可产生更精确、全面且预后准确的诊断报告,在多灶腺泡腺癌伴瘤间异质性、弥漫性癌(导管腺癌和间叶起源乳腺癌)及导管腺癌合并腺泡腺癌病例中尤为必要;此类病例制定治疗计划时应优先考虑影像生物标志物而非分子生物标志物。

研究设计与样本

  • 研究纳入2008-2019年在本院诊断且影像与分子生物标志物数据完整的乳腺癌病例2236例,采用大格式组织病理学技术记录瘤内和瘤间异质性并选择合适病灶评估分子生物标志物。

诊断标准与关键数值

  • 影像生物标志物对乳腺癌长期患者结局有强预测作用。
  • 分子生物标志物仅对单灶腺泡腺癌预测结局,在多灶腺泡腺癌中因各瘤灶分子生物标志物变异性而可靠性较低。
  • 在间叶起源乳腺癌(经典浸润性小叶癌)和导管腺癌中,分子生物标志物误导性提示预后良好,而影像生物标志物可靠提示高乳腺癌死亡风险。
  • 2236例乳腺癌中,间叶起源乳腺癌和导管腺癌占21%,但占乳腺癌死亡的45%。

临床应用与阅片要点

  • 作者认为应将影像生物标志物整合入乳腺癌诊断工作以生成更精确、全面且预后准确的诊断报告;在多灶腺泡腺癌伴瘤间异质性、弥漫性癌(导管腺癌和间叶起源乳腺癌)及导管腺癌合并腺泡腺癌病例中尤为必要;此类病例制定治疗计划时应优先考虑影像生物标志物而非分子生物标志物,因后者无法预测疾病严重程度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The development and refinement of breast imaging modalities offer a wealth of diagnostic information such as imaging biomarkers, which are primarily the mammographic appearance of the various breast cancer subtypes. These are readily available preoperatively at the time of diagnosis and can enhance the prognostic value of currently used molecular biomarkers. In this study, we investigated the relative utility of the molecular and imaging biomarkers, both jointly and independently, when predicting long-term patient outcome according to the site of tumour origin.

METHODS: We evaluated the association of imaging biomarkers and conventional molecular biomarkers, (ER, PR, HER-2, Ki67), separately and combined, with long-term patient outcome in all breast cancer cases having complete data on both imaging and molecular biomarkers (n = 2236) diagnosed in our Institute during the period 2008-2019. Large format histopathology technique was used to document intra- and intertumoural heterogeneity and select the appropriate foci for evaluating molecular biomarkers.

RESULTS: The breast cancer imaging biomarkers were strongly predictive of long-term patient outcome. The molecular biomarkers were predictive of outcome only for unifocal acinar adenocarcinoma of the breast (AAB), but less reliable in the multifocal AAB cases due to variability of molecular biomarkers in the individual tumour foci. In breast cancer of mesenchymal origin (BCMO), conventionally termed classic invasive lobular carcinoma, and in cancers originating from the major lactiferous ducts (ductal adenocarcinoma of the breast, DAB), the molecular biomarkers misleadingly indicated favourable prognosis, whereas the imaging biomarkers in BCMO and DAB reliably indicated the high risk of breast cancer death. Among the 2236 breast cancer cases, BCMO and DAB comprised 21% of the breast cancer cases, but accounted for 45% of the breast cancer deaths.

CONCLUSIONS: Integration of imaging biomarkers into the diagnostic workup of breast cancer yields a more precise, comprehensive and prognostically accurate diagnostic report. This is particularly necessary in multifocal AAB cases having intertumoural heterogeneity, in diffuse carcinomas (DAB and BCMO), and in cases with combined DAB and AAB. In such cases, the imaging biomarkers should be prioritised over molecular biomarkers in planning treatment because the latter fail to predict the severity of the disease. In combination with the use of the large section histopathology technique, imaging biomarkers help alleviate some of the current problems in breast cancer management, such as over- and under-assessment of disease extent, which carry the risk of overtreatment and undertreatment.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Tabár L, Dean PB, Tucker FL, et al. Imaging biomarkers are underutilised but highly predictive prognostic factors for the more fatal breast cancer subtypes. Eur J Radiol. 2023. PMID: 37542814. doi:10.1016/j.ejrad.2023.111021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。